Table 1.
Reported tumour control after Gamma Knife treatment of meningioma
| Reference | Tumour control rate at 5 years | Median follow-up (months) | Median tumour volume | Median prescription dose | Number of patients | Location |
|---|---|---|---|---|---|---|
|
Roche et al. [48] J Neurosurg, 2000 |
92.8% (5-year actuarial progress.-free surv.) | 30.5 | 5.8 cc (mean) (0.9–18.6 cc) | 28 Gy (mean) (12–50) | 92 | Cavernous sinus |
|
Aichholzer et al. [2] Acta Neurochir (Wien), 2000 |
96% (overall tumour control rate after mean FU of 48 months) | 48 (mean) | Not given | 15.9 Gy (mean) (9–25 Gy) | 46 | Skull base |
|
Nicolato et al. [44] Int. J. Radiation Oncology Biol. Phys, 2002 |
96% (5-year actuarial progress.-free surv.) | 48.2 | 8.1 cc (mean) (1–20) | 14.8 Gy (mean) (11–22.5 Gy) | 138 | Cavernous sinus |
|
Iwai Y et al. [21] Neurosurgery, 2003 |
92% (5-year actual tumour growth control rate) | 14.7 cc (mean) (1.2–101.5) | 11 Gy (mean) (8–15 Gy) | 43 | Cavernous sinus | |
|
Flickinger et al. [10] Int J Radiat Oncol Biol Phys, 2003 |
93.2% (5-year actuarial tumour control rate) | 29 | 5.0 cc (0.47–56.5) | 14 Gy (8.9–20) | 219 | Various |
|
Maruyama et al. [38] Neurosurgery, 2004 |
94.1% (5-year actuarial tumour control rate) | 47 | 5.4 cc (0.9–39.3) | 16 Gy (12–18) | 40 | Cavernous sinus |
|
Kreil et al. [31] J Neurol Neurosurg Psychiatry, 2005 |
98.5% (5-year actuarial progress.-free surv.) | 94.8 | 6.5 cc (0.38–89.8) | 12 Gy (7–25) | 200 | Skull base |
|
Zachenhofer et al. [61] Neurosurgery, 2006 |
94% (control of tumour growth) | 103 (mean) | . | 16.83 Gy (9–25 Gy) | 36 | Cranial base |
|
Lee et al. [35] Prog Neurol Surg, 2007 |
93% (5-year actuarial tumour control) | . | . | 13.9 Gy (mean) | 964 | Various (majority skull base) |
|
Kollová et al. [28] J Neurosurg, 2007 |
97.9% (5-year actuarial tumour control rate) | 60 | 4.4 cc (0.11–44.9 cc) | 12.55 Gy (6.5–24 Gy) | 325 | Various |
|
Hasegawa et al. [16] J Neurosurg, 2007 |
94% (5-year actuarial focal tumour control rate) | 62 | 14 cc (mean) | 13 Gy (mean) | 115 | Cavernous sinus |
|
Iwai et al. [20] J Neurosurg, 2008 |
93% (5-year actuarial progress.-free surv.) | 86.1 (mean) | 8.1 cc (1.7–55.3 cc) | 12 Gy (8–12 Gy) | 108 | Skull base |
|
Igaki et al. [19] Neurol Med Chir (Tokyo), 2009 |
86.9% (5-year local tumour control rate) | 53.2 (mean) | 3.9 cc (0.3–45) | 16 Gy (12–22.5) | 98 | Skull base |
|
Skeie et al. [56] Neurosurgery, 2010 |
94.2% (5-year actuarial tumour growth control rate) | 82 (mean) | 7.39 cc (mean) (0.40–28.9) | 12.4 Gy (6–20) | 100 | Cavernous sinus |
|
Flannery et al. [9] J Neurosurg, 2010 |
91% (5-year overall progress.-free surv.) | 72 | 6.1 cc (0.3–32.5) | 13 Gy (9–18 Gy) | 168 | Petroclival |
|
Hayashi et al. [17] Stereotact Funct Neurosurg, 2011 |
99% (overall control in 46 months) | 46 | 6.6 cc (mean) (0.3–50.6) | 12 Gy (10–14 Gy) | 66 | Skull base |
|
Santacroce et al. [49] Neurosurgery, 2012 |
95.2% (5-year progress.-free surv.) | 63 | 4.8 cc | 14 Gy | 3768 | Various |
|
Starke et al. [59] J Neurosurg, 2012 |
96% (5-year actuarial progress.-free surv.) | 78 | 5 cc (mean) (0.3–54.8) | 14 Gy (mean) (8–30 Gy) | 255 | Skull base |
|
Leavitt et al. [34] Int J Radiat Oncol Biol Phys, 2013 |
99% gross tumour control | 123 (mean) | 5.9 cc (0.1–30.4) | 18 Gy (12–30 Gy) | 222 | Cavernous sinus |
|
Ding et al. [8] J Neurosurg, 2013 |
70% (5-year actuarial tumour control rate) | 48.6 | 3 cc | 15 Gy | 65 | Parasagittal and para falcine |
|
Starke et al. [57] J Neurooncol, 2014 |
93% (5-year Kaplan-Meier actuarial progress.-free surv.) | 71 (mean) | 7.8 cc (mean) (0.17–36.1) | 13 Gy (5–40 Gy) | 254 | Petroclival |
|
Kondziolka et al. [30] Am J Clin Oncol, 2016 |
87.7% (10-year actuarial rates of freedom from tumour progression) | 56 | 5.5 cc | 15 Gy | 290 | Various |
|
Sheehan et al. [54] J Neurosurg, 2014 |
95% (actuarial progress.-free surv.) | 66.7 | 8.8 cc (mean) (0.05–54.8) | 13 Gy (5–30 Gy) | 763 | Sellar and parasellar |
|
Gande et al. [11] J Neurooncol, 2014 |
95% (10-year progression-free tumour control rates) | 65 | 8.5 cc (0.6–56.1) | 13 Gy (10–20 Gy) | 41 | Olfactory groove |
|
Park et al. [45] J Neurosurg, 2014 |
95% (5-year progression-free survival) | 40 (mean) | 3.0 cc (0.3–17.1) | 13 Gy (11–16 Gy) | 74 | Cerebello-pontine angle |
|
Ding et al. [7] Neurosurgery, 2014 |
95% (overall tumour control rate) 94.7% (overall 5-year progress.-free surv.) | 47 | 3.6 cc | 13 Gy | 177 | Cerebello-pontine angle |
|
Jang et al. [23] Brain Tumor Res Treat, 2015 |
94.7% (actuarial 5-year progress.-free surv.) | 37 | . | 13.9 Gy (9–19 Gy) | 628 | Various |
|
Sheehan et al. [52] J Neurosurg, 2015 |
92% (actuarial 5-year tumour control rate) | 60.1 (mean) | 6.5 cc | 13.6 Gy (8–40 Gy) | 675 | Posterior fossa |
|
Sheehan et al. [51] J Neurosurg, 2015 |
90% (5-year progression-free survival) | 28 | 5.6 cc (0.3–17.5) | 15 Gy (10–20 Gy) | 61 | Parasagittal and parafalcine |
|
Hafez et al. [13] Acta Neurochir (Wien), 2015 |
95% (5-year tumour progression-free survival in 40/62 pat) | 36 | 5.7 cc | 14.4 Gy | 62 | Cavernous sinus |
|
Starke et al. [58] J Neurosurg, 2015 |
88.6% (5-year progression-free survival) | 78 (mean) | 12.4 cc (8.1–54.8) | 13.5 Gy (4.8–30 Gy) | 75 | Skull base (large) |
|
Harrison et al. [14] J Neurosurg, 2016 |
93% (overall tumour control) | 19.5 | 3.54 cc (0.2–33.8) | Range 10–18 Gy | 252 | Various |
|
Cohen-Inbar et al. [4] Neurosurgery, 2016 |
88.1% (tumour volume control) 100% actuarial progress.-free surv.) | 102.5 | 4.7 cc (0.5–23) | 15 Gy (7.5–36) | 135 | Skull base |
|
Hoe et al. [18] J Korean Neurosurg Soc, 2015 |
98.8% 5-year local tumour control | 48 | 2.7 cc (0.2–10.5) | 13 Gy (10–18) | 320 | Various |
|
Kaprealian et al. [25] J Neurooncol, 2016 |
87% (5-year freedom from progression WHOI) | 75.9 | 3.6 cc (0.7–35) | 15 Gy (10–20 Gy) | 264 | Various |
|
Lee et al. [36] Clin Neurol Neurosurg, 2016 |
92.1% (overall control) | 46.1 (12–120) | 0.57 (0.12–1 cc) | 13.3 Gy (mean) (10–20 Gy) | 113 | Various |
|
Kim et al. [26] Clin Neurol Neurosurg, 2017 |
92.2% (60/771) (overall control) | 118.9 (mean) (36–180) | 3 cc (mean) (2.6–6.9) | 12.6 Gy (10–17 Gy) | 771 | Various |
|
Cohen-Inbar et al. [5] J Neurosurg, 2018 |
91.5% (overall tumour volume control) | 71 | 5.6 cc (0.2–54.8 cc) | 14 Gy (5–35 Gy) | 189 | Parasellar |
|
Patibandla et al. [46] World Neurosurg, 2017 |
83.4% (overall tumour control rate) | 66 (imaging FU) | 4.9 cc (0.3–105 cc) | 14 Gy (5–35 Gy) | 219 | Central skull base |